SWOG clinical trial number
CTSU/EA5163/S1709

INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis

Open
Abbreviated Title
INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung…
Status Notes
Site FAQ regarding background, eligibility, treatment, funding, and resources are available on the CTSU website under Protocol Related Documents http://www.ctsu.org.
Activated
02/28/2019
Participants
CTSU

Research committees

Lung Cancer

Other Clinical Trials

S2414
SWOG Clinical Trial Number

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)

Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
0% Accrual
Accrual
0%
Open
Phase
A082002
SWOG Clinical Trial Number

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
CTSU/NRG-LU007
SWOG Clinical Trial Number

RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open